Given a maternal serum screen indicating a 50% risk of trisomy 21 and about a 9% risk of trisomy 18 or trisomy 13, and an ultrasound showing a thickened nuchal translucency, what is the probability that the fetus has a chromosomal abnormality?

Risk Assessment for Fetal Chromosomal Abnormality

With a 50% risk for Down syndrome from maternal serum screening combined with thickened nuchal translucency on ultrasound, the probability of a chromosomal abnormality is approximately 60-70%, with the risk substantially elevated above the serum screening result alone.

Understanding the Combined Risk

The combination of positive maternal serum screening and increased nuchal translucency (NT) creates a multiplicative risk effect rather than simply additive. Here's the algorithmic breakdown:

Baseline Risk from Serum Screening

• Your maternal blood test shows 1/2 (50%) risk for trisomy 21 (Down syndrome)
• 1/11 (9%) risk for trisomy 18 (Edwards) or trisomy 13 (Patau)
• These are already extremely high-risk results that alone warrant immediate genetic counseling

Impact of Thickened NT

When NT ≥ 3 mm is present, approximately one-third of fetuses will have a chromosomal abnormality, and half of these will be trisomy 21 1. However, this statistic applies to the general screening population. In your case, you already have a 50% pre-test probability from serum screening, which dramatically changes the calculation.

The thickened NT serves as independent confirmation of increased risk. Studies demonstrate that about 85-90% of trisomy 21 fetuses will have either increased NT or positive serum markers 2, 3. When both are abnormal simultaneously, the positive predictive value increases substantially.

Specific Risk Breakdown

Based on the evidence:

• For trisomy 21: Your risk is likely 55-65% (the NT finding confirms and slightly increases your already 50% serum risk)
• For trisomy 18/13: Your risk increases from 9% to approximately 12-15% with the NT finding
• For other chromosomal abnormalities (sex chromosome abnormalities, rare trisomies): Additional 2-3% risk
• For copy number variants detectable by microarray: Additional 2-3% risk 4
• For single-gene disorders (like Noonan syndrome): Additional 5-10% risk in euploid fetuses with increased NT 1, 4

Overall probability of ANY chromosomal or significant genetic abnormality: 60-70%

Critical Next Steps - What You Must Do

Immediate Actions Required

Genetic counseling and invasive diagnostic testing (chorionic villus sampling or amniocentesis) should be promptly offered and is strongly recommended 1. The evidence is clear: there is minimal benefit in waiting for additional screening results when NT ≥ 3 mm is present 1.

Testing Options in Order of Preference

1. Invasive diagnostic testing (CVS or amniocentesis) with chromosomal microarray: This is the gold standard and will provide definitive diagnosis

   • Detects all trisomies, sex chromosome abnormalities, and copy number variants
   • Provides 99%+ accuracy
   • Can add targeted genetic testing for single-gene disorders associated with increased NT 1

2. Cell-free DNA (cfDNA/NIPT) as secondary screening: While ACOG supports this option for women with positive first trimester screening 1, this is NOT recommended as your primary next step because:

   • You already have extremely high-risk screening results
   • cfDNA only detects trisomies 21,18,13 and sex chromosome abnormalities
   • It will miss Noonan syndrome, 22q11.2 deletion syndrome, and other genetic causes of increased NT 1
   • In euploid fetuses with NT ≥ 3 mm, 10% have genetic variants like Noonan syndrome 1

Common Pitfalls to Avoid

• Do not rely on cfDNA alone - it will miss important diagnoses in your high-risk scenario
• Do not wait - time is critical for decision-making and management
• Even if genetic testing is normal, you will need:
  • Second trimester detailed anatomic ultrasound (18-22 weeks)
  • Fetal echocardiogram for cardiac defects 1
  • Serial fetal surveillance throughout pregnancy 1

If Karyotype is Normal (Euploid)

Even with normal chromosomes, risks remain elevated:

• 10% risk of structural anomalies (heart defects, brain abnormalities, abdominal wall defects) 1
• Increased risk of intrauterine demise proportional to NT thickness 1
• Mandatory second trimester fetal echocardiogram regardless of genetic results 1

Prognosis Context

The degree of NT thickening matters significantly. The risk increases proportionally with NT measurement - a 3.0-3.4 mm NT carries different implications than a 5 mm NT 4, 5. Your counseling should include the specific NT measurement to refine risk estimates further.

The combination of your screening results represents one of the highest-risk scenarios in prenatal diagnosis, warranting immediate subspecialty consultation and definitive diagnostic testing 1.